|
Sign In to gain access to subscriptions and/or personal tools.
|
Review: Developments in restenosis
Philip Chan
Clinical Sciences Centre, Northern General Hospital, Sheffield, S5 7AU UK, p.chan@ sheffield.ac.uk
Restenosis is a major complication leading to the failure of vascular procedures, including surgery, angioplasty and stenting. Major efforts including over 100 clinical trials have been made to overcome this complication, with little success to date. Issues relating to trial rationale, design, measurement and biology are addressed in this review.
Key Words: restenosis clinical trials angiotensin vascular smooth muscle
References
- Beatt KJ, Serruys PW, Hugenholtz PG Restenosis after coronary angioplasty: new standards for clinical studies. J Am Coll Cardiol 1990;15:491-8.[Abstract]
- Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.[Abstract/Free Full Text]
- Emanuelsson H., Beatt KJ, Bagger JP et al. Long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical events but not angiographic restenosis. European Angiopeptin Study Group. Circulation 1995:91(6):1689-96.
- Sahni R., Maniet AR, Voci G., Banka VS Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J 1991;121:1600-08.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Weintraub WS, Boccuzzi SJ, Klein JL et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. N Engl J Med 1994;331(20): 1331-7.[Abstract/Free Full Text]
- Teirstein PS, Massullo V., Jani S. et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997;336(24):1697-703.[Abstract/Free Full Text]
- Teirstein PS, Massullo V., Jani S. et al. Three-year clinical and angiographic follow-up after intracoronary radiation: results of a randomized clinical trial. Circulation 2000; 101(4):360-5.[Abstract/Free Full Text]
- Serruys PW, Emanuelsson H., van der Giessen W. et al. Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. Circulation 1996;93(3):412-22.[Abstract/Free Full Text]
- Serruys PW, van Hout B., Bonnier H. et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 1998;352(9129):673-81.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Vrolix MC, Legrand VM, Reiber JH et al. Heparin-coated Wiktor stents in human coronary arteries (MENTOR trial). MENTOR Trial Investigators. Am J Cardiol 2000;86(4):385-9.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Sousa JE, Costa MA,Abizaid AC et al. Sustained suppression of neo-intimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-11.[Abstract/Free Full Text]
- Teirstein PS Living the dream of no restenosis. Circulation 2001;104:1996-98.[Free Full Text]
- Berger PB, Holmes DR Jr, Ohman EM et al. Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Transluminal Coronary Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR). J Am Coll Cardiol 1996;27(1):1-7.[Abstract]
- Multicenter European Research Trial with Cilazapril after Angioplasty Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomised, double-blind placebo-controlled trial. Circulation 1992;86: 100-10.[Abstract/Free Full Text]
- Peters S., Gottins B., Trummel M., Rust H., Brattstrom A. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardiol 2001; 13(2):93-7.[Medline]
[Order article via Infotrieve]
- Amant C., Bauters C., Bodart JC et al. Bertrand ME D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation 1997;96(1):56-60.[Abstract/Free Full Text]
- Koch W., Kastrati A., Mehilli J., Bottiger C., von Beckerath N., Schomig A. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is not associated with restenosis after coronary stent placement. Circulation 2000;102(2):197-202.[Abstract/Free Full Text]
- Samani NJ, Martin DS, Brack M. et al. Insertion/deletion polymorphism in the angiotensin-converting enzyme gene and risk of restenosis after coronary angioplasty. Lancet 1995;345 (8956):1013-16.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hamon M.,Amant C., Bauters C. et al. Dual determination of angiotensin-converting enzyme and angiotensin-II type 1 receptor genotypes as predictors of restenosis after coronary angioplasty. Am J Cardiol 1998;81(1):79-81.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Meurice T., Bauters C., Hermant X. et al. Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double blind placebo-controlled trial. Lancet 2001;357(9265):1321-4.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Pratt RE, Dzau VJ Pharmacological strategies to prevent restenosis: lessons learned from Blockade of the Renin-Angiotensin System. Circulation 1996;93:848-52.[Free Full Text]
- Mann MJ, Whittemore AD, Donaldson MC et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 1999;354(9189):1493-8.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Chan P., Patel M., Betteridge L. et al.Abnormal growth regulation of vascular smooth muscle cells by heparin in patients with restenosis. Lancet 1993;341:341-2.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- McCaffreyTA, Du B., Consigli S. et al. Genomic instability in the type II TGF-beta1 receptor gene in atherosclerotic and restenotic vascular cells. J Clin Invest 1997;100(9):2182-8.[Web of Science][Medline]
[Order article via Infotrieve]
- Scott S., O'Sullivan M., Hafizi S., Shapiro LM, Bennett MR Human vascular smooth muscle cells from restenosis or in-stent stenosis sites demonstrate enhanced responses to p53: implications for brachytherapy and drug treatment for restenosis. Circ Res 2002;90:398-404.[Abstract/Free Full Text]
- Kondo J., Sone T., Tsuboi H. et al. Effect of quinapril on intimal hyperplasia after coronary stenting as assessed by intravascular ultrasound. Am J Cardiol 2001;87(4):443-5,A6.[Medline]
[Order article via Infotrieve]
- . Keegan J. The First World War. Pimlico, London; ISBN: 0712666451, November 1999.
Journal of Renin-Angiotensin-Aldosterone System, Vol. 3, No. 3,
145-149 (2002)
DOI: 10.3317/jraas.2002.033

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
|
|